Zai Lab Shares Rise After Karuna Therapeutics Reports Positive KarXT Data
August 08 2022 - 8:03AM
Dow Jones News
By Chris Wack
Zai Lab Ltd. shares were up 10% to $50 after the company said
its partner, Karuna Therapeutics Inc., reported positive top-line
results from its Phase 3 trial evaluating the efficacy, safety and
tolerability of its lead investigational therapy, KarXT
xanomeline-trospium, in adults with schizophrenia.
Zai Lab has an exclusive license agreement with Karuna
Therapeutics for the development, manufacturing, and
commercialization of KarXT in Greater China, including mainland
China, Hong Kong, Macau and Taiwan.
Karuna Therapeutics said the trial met its primary endpoint,
with KarXT demonstrating a statistically significant and clinically
meaningful 9.6-point reduction in the Positive and Negative
Syndrome Scale, or PANSS, total score at the fifth week.
KarXT also showed an early and sustained statistically
significant reduction of symptoms, as assessed by PANSS total
score, starting at the second week, and maintained the reduction
through all time points in the trial, the company said.
The KarXT trial also met secondary endpoints, demonstrating a
statistically significant reduction in symptoms of schizophrenia,
the company said.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
August 08, 2022 07:48 ET (11:48 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Zai Lab (NASDAQ:ZLAB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zai Lab (NASDAQ:ZLAB)
Historical Stock Chart
From Apr 2023 to Apr 2024